Elosulfase alfa: First global approval

Drugs

Volumn 74, Issue 6, 2014, Pages 713-718

  Sanford, Mark ^b   Lo, Jin Han ^a  

^a Adis R and D Insight   (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ELOSULFASE ALFA; N ACETYLGALACTOSAMINE 6 SULFATASE; GALNS PROTEIN, HUMAN; N ACETYLGALACTOSAMINE 4 SULFATASE;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTICLE; AUSTRALIA; BRAZIL; CANADA; CHILL; ENZYME REPLACEMENT; EUROPEAN MEDICINES AGENCY; FATIGUE; FEVER; HEADACHE; HUMAN; MEXICO; MORQUIO SYNDROME; MUCOPOLYSACCHARIDOSIS; NAUSEA; RECOMBINANT DNA TECHNOLOGY; VOMITING; ANIMAL; DRUG APPROVAL; MUCOPOLYSACCHARIDOSIS IV; PATHOPHYSIOLOGY; PROCEDURES;

IVA;

ANIMALS; CHONDROITINSULFATASES; DRUG APPROVAL; ENZYME REPLACEMENT THERAPY; HUMANS; MUCOPOLYSACCHARIDOSIS IV;

EID: 84899921150     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0210-z     Document Type: Article

References (13)

1. Algahim MF, Almassi GH. Current and emerging management options for patients with Morquio A syndrome. Ther Clin Risk Manag. 2013;9(1):45-53.
2. BioMarin Pharmaceutical Inc. Vimizim (elosulfase alpha) injection, for intravenous use: US prescribing information. 2014. http://www.accessdata.fda. gov/drugsatfda-docs/label/2014/125460s000lbl.pdf. Accessed 5 March 2014.
3. Montano AM, Tomatsu S, Gottesman GS, et al. International Morquio A Registry: clinical manifestation and natural course of Morquio disease. J Inherit Metab Dis. 2007;30(2):165-74.
4. Harmatz P, Mengel KE, Giugliani R, et al. The Morquio A clinical assessment program: baseline results illustrating progressive, multisystemic clinical impairments. Mol Genet Metab. 2013;109(1):54-61.
5. BioMarin Pharmaceutical, Inc. Vimizim marketing application submitted to ANVISA in Brazil [media release]. 2013. http://www.bmrn.com.
6. US Food and Drug Administration. FDA approves Vimizim to treat rare congenital enzyme disorder [media release]. 2014. http://www.fda.gov/newsevents/ newsroom/pressannouncements/ucm386008.html.
7. European Medicines Agency. Vimizim (elosulfase alpha): summary of opinion (initial authorisation) [media release]. 2014. http://www.ema.europa.eu.
8. BioMarin Pharmaceutical, Inc. BioMarin announces FDA approval for VIMIZIM™ (elosulfase alfa) for the treatment of patients with Morquio A syndrome [media release]. 2014. http://www.BMRN.com.
9. US Food and Drug Administration, Center for Drug Evaluation and Research. Briefing Document: Vimizim (elosulfase alpha) for patients with mucopolysaccharidosis type IVA (MPS IVA; Morquio syndrome). 2013. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/ drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm375126.pdf. Accessed 5 March 2014.
10. BioMarin Pharmaceutical. Vimizim (elosulfase alfa) for the treatment of mucopolysaccharidosis type IVA (Morquio syndrome): briefing document for the endocrinologic and metabolic drugs advisory committee 2013. http://www.fda.gov/ downloads/advisorycommittees/committeesmeetingmaterials/drugs/ endocrinologicandmetabolicdrugsadvisorycommittee/ucm375127.pdf. Accessed 27 March 2014.
11. Tomatsu S, Montano AM, Gutierrez M, et al. Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase. Mol Genet Metab. 2007;91(1):69-78.
12. Dvorak-Ewell M, Wendt D, Hague C, et al. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS ONE. 2010;5(8):e12194 [Electronic Resource].
13. Lorget F, Lee S, Lau K, et al. BMN 110 (recombinant human GALNS), an investigational enzyme replacement therapy for mucopolysaccharidosis type iva (MPS IVA or Morquio syndrome), promotes type II collagen synthesis in MPS IVA patients (abstract). Mol Genet Metab. 2012;105(2):S44.